NAGE Niagen Bioscience Inc

$NAGE The lowest P/E ratio ever for NAGE: AI Overview With a simulated stock price of $2.65 per share, the price-to-earnings (P/E) ratio for Niagen Bioscience Inc. (NAGE) is approximately 13.95. (I am adding shares today.)

$NAGE Question to AI - What is the fair value of NAGE stock now? The estimated fair value for Niagen Bioscience (NASDAQ: NAGE) ranges between $9.00 and $13.60 per share, according to prominent intrinsic valuation models and equity analysis platforms. Financial platforms like Simply Wall St recently updated their fair value estimate to $9.00 (down from a previous model of $12.00), while an alternative growth narrative pegs its intrinsic worth as high as $13.60. [1, 2] With the stock currently trading at $2.92, Niagen Bioscience is considered significantly undervalued by the market. Wall Street analysts share this bullish sentiment, maintaining a "Strong Buy" consensus with a 12-month average price target of $10.33 to $12.08, representing an upside potential of over 250%. [1, 2, 3, 4, 5]

$NAGE I recently was on an Alaska cruise where OneSpaWorld offered Niagen IV treatments. I asked them if it was selling well. The response was that it was doing so, and that customers often came back up the next day or two enthusiastic about their treatment. OneSpaWorld (OSW) currently offers it on over 90 ships. Niagen Bio and OSW have a deal where OSW explains to its customers that they can maintain the benefits at home by subscribing for oral TruNiagen, and OSW gets a piece of the action through the discount code used in making the subscription. The one-time treatment on-board is an expensive introduction to Niagen. Additionally, some will go to one of the more than 1,700 clinics now offering Niagen Plus IVs in the US, and some will likely buy the at-home injectables. Just for fun, if the spas on 90 ships sell even two IVs per day for 250 calendar days and Niagen Bio nets $100 for each, Niagen Bio would net over 4.5M dollars per annum and increase its sales going forward.

$NAGE Nage has lots of positive narrative. now it needs lots of positive execution/substance/ higher sales, revs, earnings. bring it on NAGE!

$NAGE shorts covered down to 3,996,318 shares. If shorts are smart enough to buy to cover, is NAGE smart enough to buyback stock now too?

$NAGE attends LD Micro 20th Annual Main Event, with CEO Robert Fried speaking on Oct 21.

$NAGE My biggest carrier of loss by a mile in my portfolio.... and thinking i was green with this and not selling it then is making me sick to the stomach... Next ER should be a massive banger to lift this from sinking further. Have to wait, at this point i have no choice.

$NAGE FYI Only. Update on Abbvie's Parkinson's Treatment Sept 25 (Reuters) - The US Food and Drug Administration has approved AbbVie's (ABBV), opens new tab treatment for Parkinson's ​disease in adults, the health regulator's website showed ‌on Friday. The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes ​as a once-a-day pill.

$NAGE not NR but Niacin which is another B3 precursor.Maybe NR might be able to get similar results.

$NAGE I know it’s Niacin a toe B3 vitamin but maybe NR might be worth while exploring since they are both NAD precursors.

$NAGE For well over a year now, this stock has done nothing but decline. Many analyst's short and long term price predictions are bad. Who wants to wait until 2030 for "possible approval" of their pharmaceutical efforts? Just imagine what would happen to this stock if there was an issue with their only supplier. Has anyone heard any more about the class action law suits brought against them?

$NAGE file:///var/mobile/Library/SMS/Attachments/1f/15/A4F72AD2-9C1D-42AF-89BA-71293CF376E6/Message.pdf

$NAGE In my research I have found that some oncologists have recommended avoiding NR for people with active cancer or are on chemotherapy. It seems NR can feed cancer cells and protect them from chemotherapy.

$NAGE Not log ago I predicted $2.65, but I did not think it would get there so quick. Get out while you can....

$NAGE worst stock in the port. Down too much to do anything other than pray and wait. I actually appreciate that i still have it...painful lesson reminder to not allow positions to get down too much, early trading mistake. Maybe one day it will gain traction and reverse this seemingly endless trickle to 0. GL to all of us.

$NAGE conceivably, they could fund close to the entirety of 4168 development buy rotating their $$ into 6mo T-bills.